Previous 10 | Next 10 |
2024-02-12 17:28:31 ET More on Quoin Pharmaceuticals Seeking Alpha’s Quant Rating on Quoin Pharmaceuticals Historical earnings data for Quoin Pharmaceuticals Financial information for Quoin Pharmaceuticals Read the full article on Seeking Alpha ...
ASHBURN, Va., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company exclusively focused on the development and commercialization of innovative therapies that treat rare and orphan dise...
Positive initial data and clean safety profile catalyze optimization plan Size of both ongoing clinical trials significantly increased Lower dose eliminated from blinded trial Dosing frequency changed to twice-daily from once-daily for both trials ASHBURN, Va., Dec. 13, 20...
2023-11-09 10:59:32 ET More on Quoin Pharmaceuticals Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Quoin Pharmaceuticals Historical earnings data for Quoin Pharmaceuticals Financial information for ...
2023-11-09 10:51:04 ET Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Gordon Dunn – Chief Financial Officer Michael Myers – Chief Executive Officer Conference Call Participants ...
Company reported positive clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study Positive benefits were observed across a number of clinical endpoints including pruritus, Investigator skin scoring system and patient global assessment ...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Quoin Pharmaceuticals Ltd. (QNRX) is expected to report $-2.4 for Q3 2023
ASHBURN, Va., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its third quar...
Available Clinical Data from Six Subjects Demonstrates Well Defined Efficacy Signals Across a Number of Study Endpoints No Safety Concerns Observed in the Study to Date ASHBURN, Va., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company...
News, Short Squeeze, Breakout and More Instantly...
Quoin Pharmaceuticals Ltd. Company Name:
QNRX Stock Symbol:
NASDAQ Market:
Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseases UCC’s proprietary dissolvable microneedles technology and other approaches will be utilized to optimize the local delivery ...
FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and International patent filed for novel Netherton Syndrome combination product Cash runway extended into late 2025 ASHBURN, Va., May 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals...
ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage specialty p...